Introduction: Individuals who use the nicotine patch are more likely to quit smoking than those who receive placebo or no medication. However, studies have not yet examined the association between actual daily nicotine patch wear time during the early phase of a smoking cessation attempt and later smoking abstinence. The purpose of this study was to address this gap in the literature.

Methods: Participants who enrolled in a safety-net hospital smoking cessation program were followed for 13 weeks (i.e., 1 week pre-quit through 12 weeks post-quit). Participants completed in-person assessments and daily ecological momentary assessments on study provided smartphones. Multivariate logistic regressions were used to determine if daily patch wear time during the first week post-quit predicted 7-day biochemically verified point prevalence smoking abstinence 4 and 12 weeks following the scheduled quit date. Demographic characteristics and smoking behaviors were adjusted as covariates.

Results: Participants (N=74) were primarily non-White (78.7%) and most (86%) had an annual household income of <$20,000. Greater average hours of daily nicotine patch wear time during the first week post-quit was associated with a greater likelihood of abstinence at the 4 and 12 week post-quit visits (aOR=2.22, 95% CI:1.17-4.23; aOR=2.24, 95% CI:1.00-5.03). Furthermore, more days of wearing the patch for ≥19h was associated with a greater likelihood of abstinence at the 4 and 12 week post-quit visits (aOR=1.81, 95% CI:1.01-3.22; aOR=2.18, 95% CI:1.03-4.63).

Conclusions: Greater adherence to the nicotine patch early in a quit attempt may increase the likelihood of smoking cessation among socioeconomically disadvantaged adults.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drugalcdep.2016.10.013DOI Listing

Publication Analysis

Top Keywords

nicotine patch
12
patch wear
12
wear time
12
smoking abstinence
12
daily nicotine
8
ecological momentary
8
smoking cessation
8
smoking
7
daily
4
patch
4

Similar Publications

Smoking cessation and harm reduction: a systematic overview of ongoing, randomized controlled trials.

BMC Psychiatry

December 2024

Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen University, Pauwelsstraße 30, Aachen, 52074, Germany.

Background: Smoking remains one of the major public health threats, necessitating substantial scientific and societal interest in further developing and implementing systematic, smoking cessation trials. This review examines ongoing randomized controlled trials (RCTs) on smoking cessation and harm reduction, focusing on adherence to German S3 guidelines for tobacco dependence and identifying areas needing further research and neglected aspects in the implementation of treatment guidelines for tobacco dependence.

Methods: A systematic search was conducted on the International Clinical Trials Registry Platform, comprising multiple trial registries worldwide, to identify ongoing RCTs focusing on smoking cessation and harm reduction.

View Article and Find Full Text PDF

Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial.

Am J Psychiatry

December 2024

Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston (Kypriotakis, Cinciripini, Minnix, Beneventi, Karam-Hage, Blalock); Department of Pediatrics, University of Texas Medical School at Houston (Green); Pfizer Inc., New York (Lawrence); Department of Psychiatry, University of California, San Diego, La Jolla (Anthenelli); Department of Psychiatry, University of Colorado, Aurora (Morris).

Objective: The aim of this study was to compare the safety and efficacy of the leading smoking cessation medications among individuals with current versus past major depressive disorder (MDD).

Methods: This was a secondary analysis of a randomized, double-blind trial over 12 weeks with varenicline or bupropion, followed by a 12-week assessment, in participants ages 18-75 with past (N=2,174) or current (N=451) MDD or without psychiatric disorders (N=4,028). Interventions included 12 weeks of pharmacotherapy with placebo, nicotine replacement therapy (NRT; nicotine patch), bupropion, or varenicline, and brief counseling.

View Article and Find Full Text PDF

Introduction: Concerns about potential side effects remain a barrier to uptake of Food and Drug Administration (FDA)-approved smoking cessation pharmacotherapy [i.e., varenicline, bupropion, nicotine replacement therapy (NRT)].

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the mental health effects of electronic nicotine delivery systems (ENDS) on adolescents aged 16-18 in New Zealand who consider themselves addicted, revealing significant physical and mental health consequences.
  • - Four main themes emerged from the interviews: the negative impact on health, loss of enjoyment from ENDS use, feelings of stigma and judgment from peers, and various negative emotions affecting self-perception.
  • - The findings highlight the urgent need for policies to limit youth access to ENDS and recommend empathetic support for young individuals attempting to quit.
View Article and Find Full Text PDF
Article Synopsis
  • * Various smoking cessation methods exist, including nicotine replacement therapies and medications like varenicline and bupropion, with new options like cytisine and faster-acting NRTs being developed, enhancing choices for those trying to quit.
  • * Personalizing cessation strategies by assessing individual responses and preferences can lead to more effective treatment outcomes, including the potential use of combination therapies for those who need additional support.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!